SAN FRANCISCO, June 22, 2017 /PRNewswire/ --
The global erythropoietin (EPO) drugs market is expectedto reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market.
According to the statistics published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, over 3 million people are affected by anemia every year and this number is expected to increase over the forecast period. This showcases the need for erythropoietin-stimulating agents in the coming years.
Introduction of novel drugs and their cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness is also expected to serve this industry with lucrative opportunities. For instance, development of numerous biosimilars in the European market is expected to gain traction and increase their usage rates, owing to associated benefits such as less time required for approval, cost-efficiency, and enhanced therapeutic effect.
Companies are involved in extensive R&D initiatives for development of innovative molecules and discovering new therapeutic areas for existing drugs. For instance, in April 2016, Sandoz received approval from the European Commission for use of its biosimilar Binocrit in nephrology indications, thereby extending the therapeutic area of its product portfolio.
Moreover, many of the industry players in the U.S., Europe, and Asia Pacific are involved in the development of new biosimilars. For example, Biocon's subsidiary Syngene International entered into an agreement with Bristol-Myers Squibb to extend their drug discovery and development program in India. This enables Biocon to enhance its erythropoietin drugs portfolio. Expected product approvals in the coming years are anticipated to fuel market growth.
Browse full research report with TOC on "Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market
Further key findings from the report suggest:
Browse related reports by Grand View Research:
Grand View Research has segmented the erythropoietin (EPO) drugs market on the basis of the drug class, product, application, and region:
Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: email@example.com
SOURCE Grand View Research, Inc.
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All